GSK's Jemperli Rectal Cancer Filing Signals Biologics Capacity Shift

The FDA has accepted for priority review a supplemental application for GSK’s Jemperli (dostarlimab).¹ The antibody blocks the programmed death receptor-1 pathway, as a treatment for previously untreated stage II and III rectal cancer that is mismatch repair deficient or microsatellite instability-high. The agency has set a target decision date of February 2027, and the filing is also eligible for an expedited review pathway that could move that date earlier.

If cleared, the therapy would be positioned as the first immunotherapy capable of eliminating or delaying the need for chemotherapy, radiation, and surgery in this patient subgroup.¹ Rectal cancer affects roughly 770,000 people globally each year, and mismatch repair deficient or microsatellite instability-high tumors account for an estimated 5-10% of cases. These tumors carry a genetic defect that impairs their ability to repair DNA damage, a characteristic that tends to make them more responsive to immune-based treatment.

What Did the Underlying Trial Demonstrate?

The application rests on data from a global, open-label, single-arm phase II trial enrolling 154 patients.¹ Participants received nine cycles of the antibody over six months, delivered as an intravenous infusion every three weeks. The trial's primary objective was a sustained 12-month clinical complete response, meaning no detectable signs of cancer at least a year after treatment began, and the study met that objective. Interim safety data were described as consistent with the antibody's established profile across other solid tumors. Full results are expected to be presented at a scientific congress later in 2026.

The filing builds on earlier investigative research, which first showed that this class of antibody could produce complete responses in this patient population without surgery, radiation, or chemotherapy.² The submission was also accepted under Project Orbis, a coordinated international review framework that allows multiple regulatory authorities to evaluate an application in parallel, though each country's decision remains independent.

What Biological Mechanism Explains Such a Strong Response?

Researchers behind the foundational trial noted that tumor mutational burden alone may not fully explain the response, pointing instead to a possible role for the gut microbiome in amplifying antitumor immunity.² Biopsy analysis showed an initial surge in PD-L1-positive and CD8-positive T cells, followed by a buildup of CD20-positive B lymphocytes forming tertiary lymphoid structures, a pattern also linked to favorable outcomes in melanoma. Investigators are now watching whether this checkpoint-blockade approach could extend to other mismatch repair deficient tumors, including pancreatic, gastric, and prostate cancers, in the neoadjuvant setting.

Why Should Professionals Pay Attention?

For a therapy already approved in other oncology indications, a new indication in a common solid tumor with a defined biomarker represents a meaningful shift in commercial and manufacturing scale.¹ A positive decision would extend an existing intravenous biologic into a substantially larger treatment-naive population, with implications for fill-finish capacity planning, cold chain logistics, and lifecycle supply forecasting for manufacturers and contract partners already producing monoclonal antibodies of this type.

The case also illustrates how biomarker-defined patient selection continues to reshape oncology development timelines.¹ A single-arm registrational design supported by a durable response endpoint, rather than a traditional randomized comparison, reflects a regulatory posture that development teams working in immuno-oncology should track closely. The use of Project Orbis in this filing is a further signal that coordinated multi-market review is becoming a standard feature of oncology submissions, with direct consequences for how development and regulatory affairs teams sequence global filing strategy and manufacturing readiness across regions rather than treating each market as a sequential, standalone process.

References

1. GSK. Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer. Press Release. August 24, 2026. https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-accepted-for-priority-review-by-the-us-fda/
2. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med. June 5, 2022;386(25):2363-2376. doi:10.1056/NEJMoa2201445